is in Thank The potential are need be important part the benefit has Rita. to aspirin of you, and this millions innovation eager we to of transformation for that market patients.
for our defined you the people As who a target secondary heart is vascular prevention know, have market VAZALORE population or a as undergone have stroke procedure. attack, experienced
billion aspirin at than represents are XX can for We target are treating are believe and who potential in also play We million candidates huge targeting vascular VAZALORE an $XX opportunity therapy. patients a representing or diabetics event important having audience an to for more which higher initial a for together considered be role groups, both market VAZALORE. risk a
consumer. Our engaging raising doctor will important the key role constituents, VAZALORE in our are the play to who mind aspirin though awareness, a VAZALORE benefit on prelaunch activities critical centered can in from professional, even recommending and education the healthcare product retailer to keep It’s that therapy. is and patients an the daily three over-the-counter life-long
research pay and our are willing for their doctor seek will patients product a for as when the the OTC product for recommends we to be targeting, it. a patient, in premium store an And confirms will out that they
We and each and to know I it with and prescribing bit critical making that aspirin. our versus its important to of a aspirin data one to decisions would the to of these VAZALORE action both mechanism comes when discuss further. data-driven professionals specialist that information to are and launch provide like the healthcare supporting continue unique performance them community and we is regular groups enteric-coated
use aspirin foundational and for secondary this most the to affirm is clarifying its from of Part therapy which patients benefit prevention.
to five of Some than lower key two physicians metrics the VAZALORE times higher offers times aspirin absorption and really better response resonate coated platelet and with XX% regular that are than of ulcers aspirin. up risk that
our data, in for have publication developed compelling will to inform neurology cardiovascular major presence treating their they a physicians at at of cardiovascular this share and patients conferences need we’ve understand data increased strategy disease. the to risk To and
In of our and presented a was ESC world-renowned advisory Dr. cardiologist the Lipid-Based was September, of at Society in Assessment the crossover study. Paris. results a of Aspirin prospective, our abstract Dominick lead Congress Cardiology, and interventional member early board Formulation, Pharmacokinetic presented esteemed randomized and Angiolillo, author of a the entitled the European abstract Pharmacodynamic scientific
data reliable of XXX formulation relief novel and ESC supported VAZALORE aspirin. fast mg demonstrated its at presented the aspirin liquid absorption approval with that and immediate is to which data The the delivers FDA’s that vaccine is bioequivalent
benefit with findings, with studies ulcers These results together showing in suggest VAZALORE compared compound aspirin superior options. profile currently the has from with significant novel risk erosions gastric to reductions a previous risk provide our and the potential available that of
cardiologists Thrombosis are and was attendance abstract share and published in presentation to in well simultaneously very that received happy The the the Journal of by was Thrombolysis. we
a Dr. continuing the from University aspirin of Than cardiovascular education Eye. Stone chaired critical symposium, the the attended we disease. the Dr. which TCT while entitled of therapy Conference, where sponsored in the Therapeutics, Angiolillo Aspirin Transcatheter Interventionalist: Following Florida Cardiovascular ESC, Mount the we of treatment this from role event addressed Annual More Sinai and Meets Gregg the for medical
commercial and is sponsored This through PLx extremely months to build the to Cardiovascular brand the us important key up for among, leaders. field provided. grant and partnership in experts was an event the educational with Foundation This supported Research in was well-attended that with are healthcare These awareness our thought these excellent raise professionals launch. platform leading familiarity conferences and in an engagement
our for publication presence journals. We all in key and plan conferences cardiology, to we data Going pharmacy at next forward, over plan expand to neurology, peer-reviewed few quarters. the generate
to the now trade. Turning
to be our key and they commercial life for category with shift VAZALORE speaks to planning a new we breathe have retailers to initiated into the phase. has around aspirin to flat several very been that interactions enthusiasm retailers therapy This continue as the shown declining. as look innovation Our positive
importance have therefore having an These for the attack motivated consumer or doctor’s effort stroke. and the indicated voice and rely I take their follow that are heavily would to their in health quite to purchase own on decision a lastly, strong recommendation patients who to responsibility guidance. They a like critical And intention avoid a to in VAZALORE. the a heart highlight typically of has very
are consumer-focused significant the are of position in All VAZALORE of cardiovascular new We as these are currently success we and care campaigns. of groups very patients. treatment that the educational the standard high-risk developing making are we VAZALORE to of marketing to critical pleased three progress
aspirin eager patients therapy for novel professionals require unmet growing, of the me aspirin. who by enthusiasm medical maintenance a is critical healthcare for community that address to doses are this Let conclude for new need today life-long saying aspirin within the a medical
are a we we transformative. of that toward excited launch be are approval believe We will and advancing product that
open the call like with Operator, I’d go for questions. that, instructions. With ahead the to please
